News

Read Our News and Insights

Featured news

AKYNZEO® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving Moderately Emetogenic Chemotherapy with additional predictive factors

Results from the MyRisk clinical trial, accepted for publication in the Annals of Oncology, will be presented today at ESMO 2025 as an oral presentation

17 October 2025

Life-cycle development
17/10/2025

AKYNZEO® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving Moderately Emetogenic Chemotherapy with additional predictive factors

Results from the MyRisk clinical trial, accepted for publication in the Annals of Oncology, will be presented today at ESMO 2025 as an oral presentation

Life-cycle development
02/04/2025

Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)

Partnership
13/03/2025

AnaCardio receives patent grant in Europe for AC01

Partnership
29/01/2025

Knight Therapeutics and Helsinn Healthcare SA expand relationship and enter into exclusive license, distribution, and supply agreement for Onicit®

Partnership
08/01/2025

Helsinn Group and ESTEVE sign a partnership agreement renewal to commercialize AKYNZEO® and ALOXI® in Germany

Partnership
10/10/2024

Helsinn attends EORTC annual meeting 2024 with a focus on Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL)